- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02522494
Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits (TELEHEALTH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Clinical video telehealth (CVT) offers the opportunity for more efficient access to high quality primary and specialist care for Veterans. Enthusiasm for CVT is especially high in the VA given geographical separation between many Veterans and their providers at VA Medical Centers. However, because CVT encounters are by nature less personal than in-person visits, communication during CVT visits may be more challenging for both patients and providers resulting in less patient-centered communication. Less personal visits may have less exchange of information, lower satisfaction, less trust, and poorer outcomes. Indeed, research comparing CVT with in-person consultations found that patients in CVT visits were more passive and that CVT interactions were dominated by providers when compared with in-person visits.
This project will leverage prior work from two HSR&D-funded pilot projects to improve provider - patient communication for Veterans with type 2 diabetes mellitus. In a short-term project, SHP-08-182, the investigators conducted focus groups to elicit and understand patients' barriers to communicating with their providers. This qualitative work was used in a subsequent pilot project, PPO-08-402 to develop an educational video to encourage Veterans to use active participatory communication in their visits to providers. This work was successfully completed and the product is a 10-minute video that, in testing, was found to be acceptable and feasible to show to VA patients immediately preceding their medical encounters.
Objectives: The investigators goal in this project is develop and test a video intervention and to also develop pamphlets for patients and providers to encourage active and positive communication in CVT medical interactions. The investigators goal was developed with and is supported by the project's operational partner the Office of Telehealth Services and is integral to the goal to ensure patient-centered care in new models of care. Patient-centered communication in medical interactions is critical and plays an important, but often overlooked, role in the delivery of health services.
There are two aims. First, the investigators will develop educational interventions to encourage patients and providers to use active communication behaviors during CVT visits. Second, the investigators will conduct a randomized trial of the video and pamphlet (intervention) vs. pamphlet alone (comparison) in a two-arm randomized effectiveness trial. The investigators will evaluate for improvement in visit outcomes including patient and provider measures of patient-centered care and communication, reduction in several common barriers to clinical improvement, and improved medication adherence measures and hemoglobin A1c. In addition, the investigators will assess the mediators and moderators of the relationship of the intervention condition to outcomes.
Methods: The project will have two phases. In the initial phase of the proposed project the investigators will develop the video intervention. Video development will include qualitative interviews with stakeholders and patients regarding CVT barriers and perceived benefits. The investigators will use several existing resources and an expert panel of co-investigators and consultants to bring these elements together and produce the intervention. In phase 2 the investigators will conduct a randomized trial of the intervention, evaluating for improvement in a number of outcomes.
Impacts: The educational tools will be deliverables that could be used prior to CVT visits to improve communication and could serve as a paradigm for developing communication aids for other medical conditions and other clinical settings. The investigators will evaluate whether the educational intervention will help improve communication and will be associated with better visit and intermediate outcomes. Educational tools that encourage more patient-centered communication during CVT encounters may allow more rapid acceptance of CVT, thereby improving access to healthcare and enhancing the operational mission of the project's partner.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Jesse Brown VA Medical Center, Chicago, IL
-
Chicago, Illinois, United States, 60611
- Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of type 2 diabetes mellitus,
- Hemoglobin A1c not controlled,
- Adults,
- Age 18 or older
Exclusion Criteria:
- Dementia,
- Lives in skilled nursing facility,
- Terminal medical condition,
- Drug-induced diabetes,
- Blind or deaf.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Intervention
Patients randomized to the intervention will view the video
|
An educational intervention delivered prior to patients' visits with primary care physicians.
Other Names:
An educational intervention delivered prior to patients' visits with primary care providers.
Other Names:
|
|
Other: Pamphlet alone
Patients randomized to the pamphlet alone will only receive the pamphlet
|
An educational intervention delivered prior to patients' visits with primary care physicians.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HgbA1c
Time Frame: At the baseline (Pre-CVT visit interview) and post-intervention (Post-CVT visit interview). All available values were restricted to one year before Baseline (Pre-Visit Interview) and from 30 days to 6 months past Post-CVT visit Interview.
|
HgbA1c is regarded as the standard laboratory measurement (blood test) for assessing the control of diabetes over approximately three months preceding the test.
HgbA1c is usually checked several times a year in patients with poorly controlled diabetes.
|
At the baseline (Pre-CVT visit interview) and post-intervention (Post-CVT visit interview). All available values were restricted to one year before Baseline (Pre-Visit Interview) and from 30 days to 6 months past Post-CVT visit Interview.
|
|
Communication Self-efficacy
Time Frame: At the baseline (Pre-CVT visit interview) and post-intervention (interview within one week past CVT visit)
|
Communication Self-Efficacy (pre and post visit) is the degree to which a patient feels able to interact with his/her provider in order to provide information about problems, obtain desired information about diagnosis, treatment and prognosis, and participate in formulating a plan.
The Perceived Efficacy in Physician-Patient Interactions scale (PEPPI) is a valid and reliable measure of patients' perceived self-efficacy in interacting with physicians (alpha 0.83).
The short form of the PEPPI (PEPPI-5) has 5-items.
Score on the PEPPI-5 ranges from 5-25.
Higher scores reflect a better perceived self-efficacy in interacting with physicians.
|
At the baseline (Pre-CVT visit interview) and post-intervention (interview within one week past CVT visit)
|
|
Consultation Care Measure (CCM)
Time Frame: post-intervention (interview within 1 week after CVT visit)
|
Consultation Care Measure (CCM) assesses patient-centered care and patient-centered communication.
Patients rate such factors as their providers' (1) communication and partnership, (2) personal relationship, (3) health promotion, (4) positive and clear approach to problem, (5) interest in effect on life on a 21-item scale, each item scores from 1 (strongly disagree) to 5 (strongly agree).
Scores can range from 21 to 105.
The higher scores mean a better patients' experiences with their provider.
|
post-intervention (interview within 1 week after CVT visit)
|
|
Adherence (Self-reported)
Time Frame: 4 weeks after the CVT visit
|
Self-reported adherence is measured using a brief questionnaire - a general measure of adherence to providers' recommendations and includes 5 items and is scored on a 6-level Likert-type scale ranging from "none of the time" to "all of the time".
Scores range from 0-100 (after normalizing the standard 6-30 range) with higher numbers reflecting better adherence.
Adherence using this measure is assessed with a brief telephone survey 4 weeks following the visit.
|
4 weeks after the CVT visit
|
|
Medication Adherence (MPR)
Time Frame: 6 months
|
Medication adherence will be assessed with a medication possession ratio (MPR) for diabetes medications.
|
6 months
|
|
Adherence at 1 Year
Time Frame: 1 year
|
Medication adherence will be assessed with a medication possession ratio (MPR) for diabetes medications.
|
1 year
|
|
Consultation and Relational Empathy (CARE)
Time Frame: Post-intervention (interview within one week past CVT visit)
|
Consultation and Relational Empathy (CARE) Measure - is a tool for measuring patients' perceptions of relational empathy in the consultation.
In this 10-item questionnaire patients rate the statements about their doctor's understanding their concern, showing care, and etc. during the recent CVT visit on a scale from 1 to 5 where 1 is "poor" and 5 is "excellent".
Scores can range from 10 to 50.
The higher score means a better patient's perception of empathy in consultation.
|
Post-intervention (interview within one week past CVT visit)
|
|
Communication Ratings
Time Frame: Post-intervention (interview within one week after CVT visit)
|
The questionnaire assesses patients' ratings of their own participatory communication behavior and patients' ratings of their providers' communication.
It is a 15-item scale with 3 sub-scales.
Patients' ratings of their (1) providers' informativeness and the extent to which the patient understands that information (information sub-scale) are measured with 5-items; (2) patients' ratings that the provider values and respects them is measured with 5-items; and (3) patients' ratings of their own communication is measured with 5-items.
This questionnaire has high internal consistency.
The scale is scored from 1 (completely disagree) to 7 (completely agree).
The total scores range from 15 to 105.
The higher scores indicate a better quality of communication.
|
Post-intervention (interview within one week after CVT visit)
|
|
Human Connection Scale
Time Frame: At the baseline (Pre-CVT visit interview) and post-intervention (Post-CVT visit interview)
|
Human Connection Scale is a 15-item questionnaire that measures the extent to which patient feel a sense of mutual understanding, caring, and trust with their physicians.
The scale is a valid and reliable measure of therapeutic alliance between patients and their physicians.
The score from 1 to 4 is used where 1 is "not at all" and 4 is "extremely".
The scores range from 15 to 60.
The higher scores indicate higher therapeutic alliance between patients and physicians.
|
At the baseline (Pre-CVT visit interview) and post-intervention (Post-CVT visit interview)
|
|
Resistance to Treatment Questionnaire (RTQ)
Time Frame: 4 weeks past CVT visit
|
Resistance to Treatment Questionnaire (RTQ) identifies the reasons for resistance to treatment and its intensity among patients with diabetes.
20-item questionnaire consists of four themes (lack of faith or dissatisfaction, emotional reasons, specific problems, factors connected to despair or failure) containing 5 items each; each item is scored from 1 (strongly disagree) to 5 (strongly agree).
The scores range from 20 to 100.
The higher scores mean more barriers to treatment (a worse outcome).
|
4 weeks past CVT visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trust in Provider Questionnaire
Time Frame: At the baseline (Pre-CVT visit interview) and post-intervention (interview within one week after CVT visit)
|
Trust in Provider is an important characteristic of provider-patient relationships and is assessed with a questionnaire.
Trust is measured pre- and post-CVT visit using a 9-item measure.
The scale is scored on a 7-point Likert scale using the anchors "strongly disagree" and "strongly agree".
The scores range from 9 to 63.
The higher scores mean a better trust in provider.
|
At the baseline (Pre-CVT visit interview) and post-intervention (interview within one week after CVT visit)
|
|
Patient Satisfaction
Time Frame: four weeks after CVT visit
|
Patient Satisfaction is assessed as the extent to which the patient is content with the relationship with her/his provider, in terms of the quality of information exchanged during medical encounters, and in terms of the demeanor of the provider toward the patient (courtesy, respectfulness, sensitivity, taking time and not being rushed).
This is a 4-item survey, patient's satisfaction is scored from 1 (not at all satisfied) to 7 (extremely satisfied).
The scores range from 5 to 35.
The higher score indicates a better patient satisfaction.
|
four weeks after CVT visit
|
|
Participatory Decision-Making
Time Frame: At the baseline (Pre-CVT visit interview) and post-intervention (Post-CVT visit interview)
|
Participatory Decision-Making Style represents the degree to which providers involve patients in decision making.
We measure patients' ratings of providers' participatory decision-making style using a 4-item scale evaluated by Heisler et al. in a study of veterans with diabetes.
The authors found it to be associated with better patient understanding of diabetes and self-management practices.
The survey scores how often provider involves patient in decision-making on a scale from 1 to 5, where 1 is "none of the time" and 5 is "all of the time".
Scores range from 4 to 20.
Higher scores mean a better outcome.
|
At the baseline (Pre-CVT visit interview) and post-intervention (Post-CVT visit interview)
|
|
Diabetes Self-Efficacy
Time Frame: At the baseline (Pre-CVT visit interview) and post-intervention (interview within one week after CVT visit)
|
The investigators used a 4-item scale to measure patients' confidence in their ability to manage their diabetes.
The survey scores patients' perception of how well they can handle their diabetes on a scale from 1 to 7, where 1 is "not at all true" and 7 is "very true".
The scores range from 4 to 28.
The higher score is validated as a predictor of better glycemic control.
The higher scores mean a better confidence in managing diabetes.
|
At the baseline (Pre-CVT visit interview) and post-intervention (interview within one week after CVT visit)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Howard S. Gordon, MD BS, Jesse Brown VA Medical Center, Chicago, IL
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SDR 12-282
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Pamphlet
-
Université de SherbrookeUniversity of OttawaCompleted
-
The University of Hong KongCompletedSmoking CessationHong Kong
-
University of BeninUBTHCompleted
-
Riphah International UniversityNot yet recruitingPrimary DysmenorrheaPakistan
-
NYU Langone HealthWithdrawnImproving Fecal Immunochemical Test (FIT) Completion RatesUnited States
-
Abramson Cancer Center at Penn MedicineCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatic Diseases | Contraception | Physician-Patient RelationsUnited States
-
IWK Health CentreUnknownCongenital Abnormalities | Musculoskeletal Diseases | Stomatognathic Diseases | Cleft Palate | Mouth Abnormalities | Stomatognathic System Abnormalities | Jaw Abnormalities | Jaw Diseases | Maxillofacial Abnormalities | Craniofacial Abnormalities | Musculoskeletal AbnormalitiesCanada
-
Thiruvananthapuram Medical CollegeCompletedType2 Diabetes Mellitus | Physical InactivityIndia
-
Rush University Medical CenterCompleted